Overview
Ika Skelin-Kardum practices practicing medicine in Zagreb, Croatia.
Their clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL) and Chronic B-Cell Leukemia (CBCL).
They are actively involved in clinical research, co-authoring 11 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Ika Skelin-Kardum
Is Ika Skelin-Kardum a top-rated expert for Chronic Lymphocytic Leukemia (CLL)?
MediFind is an objective health platform that identifies experts based on real-world data. Ika Skelin-Kardum is classified as an Experienced expert for Chronic Lymphocytic Leukemia (CLL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Ika Skelin-Kardum participate in research or clinical trials?
Yes. Ika Skelin-Kardum has published 11 articles and abstracts on conditions like Chronic Lymphocytic Leukemia (CLL). You can view a list of Ika Skelin-Kardum's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Chronic B-Cell Leukemia (CBCL)Skelin-Kardum isExperienced. Learn about Chronic B-Cell Leukemia (CBCL).
- Chronic Lymphocytic Leukemia (CLL)Skelin-Kardum isExperienced. Learn about Chronic Lymphocytic Leukemia (CLL).